BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen F, Fan Y, Hou J, Liu B, Zhang B, Shang Y, Chang Y, Cao P, Tan K. Integrated analysis identifies TfR1 as a prognostic biomarker which correlates with immune infiltration in breast cancer. Aging (Albany NY) 2021;13:21671-99. [PMID: 34518441 DOI: 10.18632/aging.203512] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu Y, Hu Y, Jiang Y, Bu J, Gu X. Targeting ferroptosis, the achilles’ heel of breast cancer: A review. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1036140] [Reference Citation Analysis]
2 Dong T, Zhang B, Zhang R, Wang C, Liu X, Wang F, Hao N, Tan K, Chang Y. Hepcidin is upregulated and is a potential therapeutic target associated with immunity in glioma. Front Oncol 2022;12:963096. [DOI: 10.3389/fonc.2022.963096] [Reference Citation Analysis]
3 Cao J, Hu C, Xu J, Han J, Zhang R, Cao M, Yuan L, Xu Z. Aberrant Expression TFR1/CD71 in Gastric Cancer Identifies a Novel Potential Prognostic Marker and Therapeutic Target. Evidence-Based Complementary and Alternative Medicine 2022;2022:1-10. [DOI: 10.1155/2022/4257342] [Reference Citation Analysis]
4 Villalobos-manzo R, Ríos-castro E, Hernández-hernández JM, Oza G, Medina MA, Tapia-ramírez J. Identification of Transferrin Receptor 1 (TfR1) Overexpressed in Lung Cancer Cells, and Internalization of Magnetic Au-CoFe2O4 Core-Shell Nanoparticles Functionalized with Its Ligand in a Cellular Model of Small Cell Lung Cancer (SCLC). Pharmaceutics 2022;14:1715. [DOI: 10.3390/pharmaceutics14081715] [Reference Citation Analysis]
5 Zhang B, Zhao J, Liu B, Shang Y, Chen F, Zhang S, He J, Fan Y, Tan K. Development and Validation of a Novel Ferroptosis-Related Gene Signature for Prognosis and Immunotherapy in Hepatocellular Carcinoma. Front Mol Biosci 2022;9:940575. [DOI: 10.3389/fmolb.2022.940575] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Chen Y, Ji H, Liu S, Xing Q, Zhu B, Wang Y. Survival Prognosis, Tumor Immune Landscape, and Immune Responses of ADAMTS14 in Clear Cell Renal Cell Carcinoma and Its Potential Mechanisms. Front Immunol 2022;13:790608. [DOI: 10.3389/fimmu.2022.790608] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Yang C, Li J, Guo Y, Gan D, Zhang C, Wang R, Hua L, Zhu L, Ma P, Shi J, Li S, Su H. Role of TFRC as a Novel Prognostic Biomarker and in Immunotherapy for Pancreatic Carcinoma. Front Mol Biosci 2022;9:756895. [DOI: 10.3389/fmolb.2022.756895] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 杨 克. Research Progress of TFRC in Gynecological Tumors. ACM 2022;12:7047-7052. [DOI: 10.12677/acm.2022.1281014] [Reference Citation Analysis]
9 Noor H, Zaman A, Teo C, Sughrue ME. PODNL1 Methylation Serves as a Prognostic Biomarker and Associates with Immune Cell Infiltration and Immune Checkpoint Blockade Response in Lower-Grade Glioma. Int J Mol Sci 2021;22:12572. [PMID: 34830454 DOI: 10.3390/ijms222212572] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]